China Veterinary Medicine Market to Reach USD 9.29 Billion by 2032, Growing at a CAGR of 10.48% During 2026–2032

The China Veterinary Medicine Market was valued at USD 4.89 billion in 2025 and is projected to grow from USD 5.11 billion in 2026 to USD 9.29 billion by 2032, registering a CAGR of 10.48% during the forecast period. Demand is primarily driven by China's large-scale livestock industry, which continues to require extensive disease prevention and animal health management solutions. According to official Chinese government statistics, the country's combined output of pork, beef, mutton, and poultry meat reached 96.63 million tonnes in 2024, representing a year-on-year increase of 0.2%. Within this total, beef production increased by 3.5% to 7.79 million tonnes, while poultry meat output expanded by 3.8%. Such production volumes necessitate the continuous use of veterinary medicines, vaccines, and biosecurity solutions to maintain animal health, productivity, and food safety standards.

The regulatory landscape is also playing a pivotal role in shaping market growth. MARA's Announcement No. 194, implemented in July 2020, eliminated the use of antimicrobial growth-promoting feed additives in livestock production, while the National Action Plan for Combating Antimicrobial Resistance (2022–2025) established a target for prescription-based antibiotic sales to exceed 80% by 2025. These measures are accelerating the transition from conventional anti-infectives toward preventive healthcare solutions, including veterinary vaccines, biologics, and advanced medicated feed products.

From a product perspective, vaccines represent the largest segment of the market, supported by China's mandatory national vaccination programs targeting diseases such as Foot-and-Mouth Disease (FMD), Highly Pathogenic Avian Influenza (HPAI), Newcastle Disease, and African Swine Fever. By animal type, poultry accounts for the largest share due to compulsory HPAI vaccination requirements and the industry's rapid production cycles, with broilers typically reaching market weight within 35–45 days.

Meanwhile, the companion animal segment is emerging as a significant growth contributor. China's pet population reached approximately 124.1 million in 2024, while annual expenditure per dog rose to approximately USD 411, reflecting increasing pet ownership and growing willingness among consumers to invest in animal healthcare products and services.

The convergence of expanding livestock production, strengthening biosecurity requirements, evolving antimicrobial resistance regulations, and rising companion animal healthcare expenditure is expected to support sustained growth of the market through 2032, as highlighted in the recent report, “China Veterinary Medicine Market Analysis, 2026.”

China Veterinary Medicine Market Highlights

The China Veterinary Medicine Market is valued at USD 4.89 billion in 2025, rising to USD 5.11 billion in 2026, and projected to reach USD 9.29 billion by 2032 at a CAGR of 10.48%.
Poultry leads demand by animal type with a 40% share, driven by mandatory HPAI vaccination and the shortest broiler production cycles among all livestock species.
Vaccines dominate product demand with a 52% share, anchored by mandatory state-led programmes covering FMD, HPAI, Newcastle disease, and African Swine Fever across production animals.
The market is moderately consolidated; the top five players collectively hold approximately 21% share, leaving significant room for domestic Chinese manufacturers and regional specialists.